NYU Cancer Health Disparity (CHD) SPORE

纽约大学癌症健康差异 (CHD) SPORE

基本信息

批准号：
10265452
负责人：
Jiyoung Ahn
金额：
$ 112.55万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-17 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10265452
关键词：
Achievement Address Adjuvant Chemotherapy Area Asians Bioinformatics Biological Biological Factors Biometry Cancer Center Cancer Control Cancer Patient Case-Control Studies Cessation of life Clinic Clinical Colon Carcinoma Colonic Neoplasms Communities Complex Comprehensive Cancer Center Coupling Data Development Ethnic Origin Exhibits Fostering Goals Head Cancer Head and Neck Cancer Health Helicobacter pylori Human Human Microbiome Human Papillomavirus Immune Incidence Individual Intervention Knowledge Lead Malignant Neoplasms Malignant neoplasm of liver Metagenomics Microbe Minority Minority Groups Neck Cancer Nested Case-Control Study New York City Participant Patients Phenotype Population Heterogeneity Prevention trial Process Prospective cohort Race Recurrence Regulation Research Research Personnel Resources Role Sampling Shapes Socioeconomic Factors Solid Therapeutic Clinical Trial Translating Treatment outcome Work base burden of illness cancer health disparity cancer prevention cancer recurrence cancer therapy clinical practice cohort colon cancer patients commensal microbes evidence base genome-wide gut microbiome high risk high risk population human microbiota immune function improved individualized prevention malignant stomach neoplasm microbial microbiome microbiota mortality multi-ethnic novel oral microbiome pathogen personalized intervention population based programs prophylactic prospective racial disparity racial diversity racial minority socioeconomic disparity tool translational research program tumor tumor-immune system interactions tumorigenesis

项目摘要

PROJECT SUMMARY Orodigestive tract (ODT) cancers, which account for 32% of cancer deaths in the US, exhibit striking racial disparities in incidence and mortality burdens. Our central hypothesis is that the human microbiome contributes to ODT cancer disparities through biologic interaction of the microbiome with the host in ODT oncogenesis. The overall objective of the NYU Cancer Health Disparity (CHD) SPORE is to develop a comprehensive translational research program to identify, understand and control the microbiota that account for orodigestive track (ODT) cancer disparities. Project 1 will focus on the relationship of the oral microbiome to racial and socioeconomic disparities in the incidence of head and neck cancer, by means of a prospective case-control study nested within 3 large highly diverse US cohorts. Project 2 will focus on the gut microbiome and Black and White racial disparities in tumor recurrence in colon cancer patients who received adjuvant chemotherapy. Our research will be strongly supported through shared Cores: (A) Administrative, (B) Biospecimen Procurement & Utilization, and (C) Biostatistics and Bioinformatics. The proposal brings together a highly transdisciplinary team of investigators that work collaboratively through every stage of the proposed research to accomplish the translational goal of this P20 application. The NYU CHD SPORE will provide new knowledge on specific human microbiota that contribute to ODT cancer disparities and will advance our understanding of the functional consequences of these microbiota in ODT oncogenesis. The knowledge gained from the proposed research in the P20 SPORE will transform current clinical practice by identifying high risk groups for ODT cancer in minority populations, that will provide the scientific basis for developing microbially-based personalized prevention, clinical decision tools, and prophylactic interventions to address ODT cancer disparities. Achievement of the P20 SPORE will lay a solid groundwork for a P50 SPORE to translate these evidence-based findings of microbial factors contributing to ODT cancer disparity into actionable practice-based interventions at the clinic and community level.

项目摘要在美国占癌症死亡的32％的Ordivestive Tract（ODT）癌症表现出惊人的种族发病率和死亡率负担的差异。我们的中心假设是人类微生物组有助于通过微生物组与ODT肿瘤发生中的宿主的生物学相互作用来实现ODT癌症的差异。这纽约大学癌症健康差异（CHD）孢子的总体目标是发展全面的翻译研究计划旨在识别，理解和控制对探测轨迹（ODT）的微生物群癌症差异。项目1将重点介绍口腔微生物组与种族和社会经济的关系通过一项嵌套的前瞻性病例对照研究，头颈癌发病率的差异 3个高度多样化的美国队列。项目2将重点关注肠道微生物组和黑白种族接受辅助化疗的结肠癌患者肿瘤复发的差异。我们的研究会通过共享核心得到强有力的支持：（a）行政管理，（b）生物循环采购和利用率，以及（c）生物统计学和生物信息学。该提案汇集了一个高度跨学科的调查员团队该研究通过拟议研究的每个阶段进行协作，以实现翻译目标此P20应用程序。 NYU CHD孢子将提供有关特定人类微生物群的新知识有助于ODT癌症的差异，并将促进我们对这些功能后果的理解 ODT肿瘤发生中的微生物群。从P20孢子中拟议的研究中获得的知识将通过确定少数族裔ODT癌的高风险群体来改变当前的临床实践，这将为开发基于微生物的个性化预防，临床决策工具和预防性干预措施以解决ODT癌症差异。 P20孢子的实现将奠定固体 P50孢子的基础工作，以翻译这些基于证据的微生物因素的发现，有助于 ODT癌症的差异是在诊所和社区层面上基于可行的实践干预措施。